Previous 10 | Next 10 |
2024-03-12 17:35:56 ET More on Spero Therapeutics Spero Therapeutics says cash and cash equivalents as of December 31 were about $76.3M Seeking Alpha’s Quant Rating on Spero Therapeutics Historical earnings data for Spero Therapeutics Financial informa...
2024-03-12 17:35:31 ET Major earnings expected after the bell on Wednesday include: UiPath ( PATH ) SentinelOne ( S ) Lennar Corporation ( LEN ) GrowGeneration Corp. ( GRWG ) Limbach Holdings ( LMB ) Read the full article on Seeking Alpha ...
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial inf...
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacteria...
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today anno...
2024-01-05 08:19:04 ET More on Spero Therapeutics Spero Therapeutics Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Spero Therapeutics Historical earnings data for Spero Therapeutics Financial information for Spero Therapeutics For fu...
In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in PIVOT-PO Phase 3 trial for tebipenem HBr in cUTI patients. Entitled to receive $95 million in development milestones, payable over two ye...
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MD...
2023-11-13 19:05:08 ET Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Conference Call November 13, 2023, 04:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations and Strategic Finance Sath Shukla - Chief Executive Officer Kamal Hamed - ...
2023-11-13 16:19:04 ET More on Spero Therapeutics Spero Therapeutics Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Spero Therapeutics Historical earnings data for Spero Therapeutics Financial information for Spero Therapeutics For fu...
News, Short Squeeze, Breakout and More Instantly...
Spero Therapeutics Inc. Company Name:
SPRO Stock Symbol:
NASDAQ Market:
Spero Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical compan...
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced tha...
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024 Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTI Received FDA Fast...